Literature DB >> 10903724

Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface.

K Denzer1, M van Eijk, M J Kleijmeer, E Jakobson, C de Groot, H J Geuze.   

Abstract

Follicular dendritic cells (FDCs) present in lymphoid follicles play a critical role in germinal center reactions. They trap native Ags in the form of immune complexes providing a source for continuous stimulation of specific B lymphocytes. FDCs have been reported to express MHC class II molecules, suggesting an additional role in the presentation of not only native, but also processed Ag in the form of peptide-loaded MHC class II. Adoptive bone marrow transfer experiments have shown that MHC class II molecules are only passively acquired. Up to now the origin of these MHC class II molecules was not clear. Here we show by cryoimmunogold electron microscopy that MHC class II molecules are not present at the plasma membrane of FDCs. In contrast, microvesicles attached to the FDC surface contain MHC class II and other surface proteins not expressed by FDCs themselves. The size and marker profiles of these microvesicles resemble exosomes. Exosomes, which are secreted internal vesicles from multivesicular endosomes, have been shown earlier to stimulate proliferation of specific T lymphocytes in vitro, but their target in vivo remained a matter of speculation. We demonstrate here that isolated exosomes in vitro bind specifically to FDCs and not to other cell types, suggesting that FDCs might be a physiological target for exosomes.

Mesh:

Substances:

Year:  2000        PMID: 10903724     DOI: 10.4049/jimmunol.165.3.1259

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  137 in total

1.  Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes.

Authors:  Valentina Zavasnik-Bergant; Ana Schweiger; Tadeja Bevec; Rastko Golouh; Vito Turk; Janko Kos
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

Review 2.  Clinical relevance of microparticles from platelets and megakaryocytes.

Authors:  Joseph E Italiano; Albert T A Mairuhu; Robert Flaumenhaft
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

Review 3.  Exosomes: immune properties and potential clinical implementations.

Authors:  Nathalie Chaput; Clotilde Théry
Journal:  Semin Immunopathol       Date:  2010-12-21       Impact factor: 9.623

Review 4.  The ins and outs of MHC class II-mediated antigen processing and presentation.

Authors:  Paul A Roche; Kazuyuki Furuta
Journal:  Nat Rev Immunol       Date:  2015-02-27       Impact factor: 53.106

Review 5.  The role of exosomes in the processing of proteins associated with neurodegenerative diseases.

Authors:  Laura J Vella; Robyn A Sharples; Rebecca M Nisbet; Roberto Cappai; Andrew F Hill
Journal:  Eur Biophys J       Date:  2007-12-07       Impact factor: 1.733

6.  Splenic CD19-CD35+B220+ cells function as an inducer of follicular dendritic cell network formation.

Authors:  Takaya Murakami; Xin Chen; Koji Hase; Ayako Sakamoto; Chie Nishigaki; Hiroshi Ohno
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

Review 7.  Germinal-center organization and cellular dynamics.

Authors:  Christopher D C Allen; Takaharu Okada; Jason G Cyster
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

Review 8.  Membrane vesicles as conveyors of immune responses.

Authors:  Clotilde Théry; Matias Ostrowski; Elodie Segura
Journal:  Nat Rev Immunol       Date:  2009-06-05       Impact factor: 53.106

9.  The Trojan exosome hypothesis.

Authors:  Stephen J Gould; Amy M Booth; James E K Hildreth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-28       Impact factor: 11.205

Review 10.  Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies.

Authors:  Johnny C Akers; David Gonda; Ryan Kim; Bob S Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2013-03-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.